MediFind

Find a Doctor

Leo Mascarenhas

Childrens Hospital Los Angeles Medical Group, Inc.
Pediatrics, Hematology, Oncology
Male
Practicing approx. 30 years

Bio


Leo Mascarenhas is a Pediatrics specialist and a Hematologist in Los Angeles, California. He has been an author on 88 peer reviewed articles and participated in 26 clinical trials in the past 15 years. Dr. Mascarenhas's top three areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Hepatoblastoma. He is licensed to treat patients in CA.

Contact

4650 W Sunset Blvd
Los Angeles, CA 90027, US

Latest Research


Latest Advance
Study
  • Condition: Rhabdomyosarcoma (RMS)
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Bevacizumab or Temsirolimus in combination with Chemotherapy
  • Number of Patients: 87
  • Published —
This study evaluated the use of bevacizumab or temsirolimus in combination with chemotherapy in pediatric patients with first relapse Rhabdomyosarcoma (RMS) with unfavorable prognosis.
Latest Advance
Study
  • Condition: Metastatic Osteosarcoma
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Regorafenib
  • Number of Patients: 42
  • Published —
The study researched the use of regorafenib for treating metastatic osteosarcoma.
Latest Advance
Study
  • Condition: Pediatric Patients with Advanced Gastrointestinal Stromal Tumor
  • Journal: Cancer chemotherapy and pharmacology
  • Treatment Used: Sunitinib
  • Number of Patients: 6
  • Published —
This trial evaluated the safety and effectiveness of sunitinib in pediatric patients with advanced gastrointestinal stromal tumor.
Latest Advance
Study
  • Condition: TRK fusion-positive tumours
  • Journal: The Lancet. Oncology
  • Treatment Used: Larotrectinib
  • Number of Patients: 24
  • Published —
This study assessed the safety of larotrectinib in pediatric patients with TRK fusion-positive tumours.

Clinical Trials


Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 50
  • Start Date: June 4, 2018
Phase 1 Trial of the LSD1 Inhibitor SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 1220
  • Start Date: May 23, 2018
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 45
  • Start Date: October 2, 2017
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 400
  • Start Date: June 5, 2017
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 72
  • Start Date: October 25, 2016
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 256
  • Start Date: November 23, 2015
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 33000
  • Start Date: October 26, 2015
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 621
  • Start Date: July 28, 2014
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 1200
  • Start Date: September 15, 2008
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 4738
  • Start Date: May 19, 2008
Umbrella Long-Term Follow-Up Protocol
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 3885
  • Start Date: March 22, 2004
Key Adverse Events After Childhood Cancer
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 10000
  • Start Date: November 6, 2000
Neuroblastoma Biology Studies

Contact

4650 W Sunset Blvd
Los Angeles, CA 90027, US

Credentials

  • Licenses
    Pediatric Hematology-Oncology in CA
  • Board Certifications
    Hematology/oncology

Insurance

Contact them to find out if they accept your insurance plan.